<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614234</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F51</org_study_id>
    <nct_id>NCT03614234</nct_id>
  </id_info>
  <brief_title>Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients</brief_title>
  <acronym>Bright 51</acronym>
  <official_title>Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Adult Patients With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of PB-102-F51 is to evaluate the long-term safety, tolerability, and efficacy
      of 2 mg/kg pegunigalsidase alfa administered intravenously every four weeks in adult Fabry
      patients who have successfully completed PB-102-F50.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study to assess the long-term safety and efficacy of pegunigalsidase
      alfa treatment of 2.0 mg/kg administered intravenously every 4 weeks. The duration of
      treatment will be up to 36 months or until pegunigalsidase alfa is available to the patient
      at the discretion of the Sponsor. Interim analyses may be performed for administrative
      purposes during the conduct of the study.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label extension study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment-related adverse events</measure>
    <time_frame>Throughout the study, 156 weeks</time_frame>
    <description>CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>At 56 and108 weeks and at the end of the study, 156 weeks</time_frame>
    <description>Estimated glomerular filtration rate (eGFRCKD-EPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac assessment</measure>
    <time_frame>At 56 and 108 weeks and at the end of the study, 156 weeks</time_frame>
    <description>Left Ventricular Mass Index (g/m2) by echocardiogram and cardiac function stress test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers for Fabry disease</measure>
    <time_frame>At 56 and 108 weeks and at the end of the study, 156 weeks</time_frame>
    <description>Plasma Lyso-Gb3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment</measure>
    <time_frame>Every four weeks throughout the duration of the study, 156 weeks</time_frame>
    <description>Record of pain medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>At 56 and 108 weeks and at the end of the study, 156 weeks</time_frame>
    <description>Protein/Creatinine ratio (UPCR), spot urine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>At 56 and 108 weeks and at the end of the study, 156 weeks</time_frame>
    <description>Short form Brief Pain Inventory (BPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom assessment</measure>
    <time_frame>At 56 and 108 weeks and at the end of the study, 156 weeks</time_frame>
    <description>Mainz Severity Score Index (MSSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>At 56 and 108 weeks and at the end of the study, 156 weeks</time_frame>
    <description>Quality of life (EQ-5D-5L)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Experimental open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegunigalsidase alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegunigalsidase alfa</intervention_name>
    <description>Recombinant human alpha galactosidase A</description>
    <arm_group_label>Experimental open label</arm_group_label>
    <other_name>PRX-102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completion of study PB-102-F50.

          2. The patient signs informed consent.

          3. Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically accepted, highly effective method of contraception. These
             include combined (estrogen- and progestogen-containing) hormonal contraception
             associated with inhibition of ovulation (oral, intravaginal, or transdermal),
             progestogen-only hormonal contraception associated with inhibition of ovulation (oral,
             injectable, or implantable), intrauterine device (IUD), intrauterine hormone-releasing
             system (IUS), bilateral tubal occlusion, vasectomised partner, or sexual abstinence.

        Exclusion Criteria:

        Presence of any medical, emotional, behavioral, or psychological condition that, in the
        judgment of the Investigator and/or Medical Director, would interfere with patient
        compliance with the requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UAB Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinica</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infusion Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Institute of Metabolic Disease</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospitals &amp; Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní poliklinika Všeobecné fakultní nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>PRX-102</keyword>
  <keyword>pegunigalsidase alfa</keyword>
  <keyword>Fabry disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

